Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8043705 | 0.80 | CYP19A1 (1.00) | CYP19A1SMN1; SMN2TP53ALDH1A1KDM4E | |
| SCHEMBL930343 | 0.79 | ADORA3 (0.59) | SMN1; SMN2TP53LMNAHTTNPC1 | |
| SCHEMBL30585815 | 0.79 | CYP19A1 (0.67) | CYP19A1SMN1; SMN2TP53ALDH1A1KDM4E | |
| SCHEMBL9230808 | 0.79 | CYP19A1 (0.67) | CYP19A1SMN1; SMN2TP53ALDH1A1KDM4E | |
| SCHEMBL6529695 | 0.79 | CYP19A1 (0.67) | CYP19A1SMN1; SMN2TP53ALDH1A1KDM4E | |
| SCHEMBL3761164 | 0.77 | MAPT (0.62) | CYP19A1SMN1; SMN2KDM4EMAPTHSD17B10 | |
| SCHEMBL14755613 | 0.76 | CYP19A1 (0.39) | CYP19A1SMN1; SMN2MAPTLMNANPC1 | |
| SCHEMBL25083884 | 0.75 | CYP19A1 (0.61) | CYP19A1SMN1; SMN2TP53ALDH1A1KDM4E | |
| SCHEMBL25883843 | 0.75 | CYP19A1 (0.61) | CYP19A1SMN1; SMN2TP53ALDH1A1KDM4E | |
| SCHEMBL5032444 | 0.74 | SMN1; SMN2 (0.73) | CYP19A1SMN1; SMN2TP53ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013031694-A1 | AMINE COMPOUND AND SALT THEREOF | 富山化学工業株式会社 (JP) | 2013-03-07 | — | — | WO | disclosed |
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| EP-2188265-A1 | PROCESS FOR PREPARATION OF AMORPHOUS LOPINAVIR | Ranbaxy Laboratories Limited (IN) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009019661-A1 | PROCESS FOR PREPARATION OF AMORPHOUS LOPINAVIR | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-12 | — | — | WO | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| CN-101103007-A | Amide compound | TAKEDA PHARMACEUTICAL (JP) | 2008-01-09 | — | — | CN | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | CYP19A1 788/4885SMN1; SMN2 2454/4885TP53 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.